Updated:
R-Pharm
R-Pharm is a privately held pharmaceutical company founded by Alexey Repik in 2001 and headquartered in Moscow. Repik entered the industry after early work in...
R-Pharm
R-Pharm is a privately held pharmaceutical company founded by Alexey Repik in 2001 and headquartered in Moscow. Repik entered the industry after early work in medical equipment distribution, scaling the firm into one of Russia's largest pharma enterprises by revenue without a public listing. The wealth origin is wholly operational — Repik retains full control and has not separated investment activity into a standalone family office. The firm deploys capital through direct corporate investment rather than external fund commitments. Manufacturing infrastructure absorbs the heaviest expenditures: a production plant in Illertissen, Bavaria, and a second in St. Petersburg produce sterile injectables, oncology drugs, and biosimilars. Licensing partnerships with global pharma majors — most notably AstraZeneca, which contracted R-Pharm to produce the adenovirus-based COVID-19 vaccine in Russia — generate recurring revenue streams. In 2017, Japanese trading house Mitsui & Co. acquired a 10% stake for $200 million, valuing the firm at $2 billion and signaling institutional appetite for its ex-Russia manufacturing footprint. The firm also holds real estate assets including a San Francisco residential property and a Moscow-area logistics lease. The operating team remains lean at the top. Alexey Repik runs the group as founder and primary decision-maker. His mother Valeria Daeva appears as owner of affiliated entity Petrusko and holds a shareholder position. Repik sits on the Russian Union of Industrialists and Entrepreneurs general council and chairs the Business Russia professional network, roles that embed R-Pharm within industrial-policy circles. No dedicated investment team, separate family office vehicle, or third-party capital is publicly disclosed. May 2022: Repik stepped down as chairman of the board while retaining ownership control, a governance move reported by Russian business media. R-Pharm is structurally distinct from any allocator archetype. It functions as an operating company — not a family office, not a fund — that generates and reinvests industrial cashflows. There is no external LP capital, no fund vehicles, and no co-investment club. The political adjacency is material: Repik has been publicly linked to Katerina Tikhonova, the daughter of Vladimir Putin, and RDIF has provided co-investment for select projects. Any institutional co-investor evaluating exposure to Russian pharma manufacturing must weigh this proximity against the firm's genuine operational scale.
General information
Firm type
Corporate Investor
Year founded
2001
AUM
Undisclosed
Location
Region
Europe
Country
Russia
City
Moscow
Corporate office
Moscow, Russia
Additional offices
Illertissen, Germany · St. Petersburg, Russia
Principals
Alexey Repik
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at R-Pharm?
Alexey Repik, the founder and primary owner, makes all material capital-allocation decisions. The firm has no dedicated investment committee, no external investment staff disclosed, and no separate family office. Strategic moves — including the Mitsui minority sale and manufacturing-plant builds — are routed through the corporate entity under Repik's direction.
Is R-Pharm a single family office or an operating company?
R-Pharm is an operating pharmaceutical company, not a family office. The Repik family wealth sits inside the corporate balance sheet. Real estate assets, aircraft, and minority stakes are held through corporate entities and affiliated LLCs rather than a dedicated family capital vehicle.
Does R-Pharm participate in fund commitments or only direct deals?
R-Pharm deploys its own corporate cashflow — there is no evidence of third-party fund commitments. Capital goes into manufacturing plants, licensing agreements, real estate acquisitions, and public-health partnerships. The 2017 Mitsui transaction was an equity sale, not a co-investment fund structure.
Where does the underlying wealth come from?
Alexey Repik's wealth originates from pharmaceutical manufacturing and distribution. He built R-Pharm from a medical-equipment trading business in the early 2000s, expanding into licensed drug production and eventually acquiring European manufacturing assets. No inherited wealth or external seed capital has been disclosed.
How is R-Pharm related to the Russian state?
R-Pharm has received co-investment from the Russian Direct Investment Fund for specific projects and holds licensing agreements tied to public-health priorities, including COVID-19 vaccine production. Alexey Repik's personal association with Katerina Tikhonova and his leadership roles in state-adjacent business councils create a governance overlay that institutional investors typically diligence separately.
Does R-Pharm maintain philanthropic structures?
Two charitable foundations are linked to the Repik network: Quench My Griefs Charitable Foundation and the Youth Entrepreneurial Initiative Foundation. Both are legally separate from the operating pharma company, though full reporting on grantmaking and governance is not publicly available.
What is R-Pharm's geographic footprint?
The firm operates manufacturing in Germany and Russia, with distribution and licensing partnerships spanning the US, Japan, Turkey, the Middle East, and North Africa. Real estate holdings include a San Francisco residential property and a Moscow-area logistics lease. No office roster beyond the manufacturing sites is disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: